Investors

IR Overview

News

Date Title  
Toggle Summary Adaptimmune Reports Third Quarter 2016 Financial Results
– U.S. Food and Drug Administration ( FDA ) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 – – Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells – – Initiated
Adaptimmune Reports Third Quarter 2016 Financial Results
– U.S. Food and Drug Administration ( FDA ) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 – – Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells – – Initiated
Toggle Summary Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the planned study of its NY‑ESO
Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the planned study of its NY‑ESO
Toggle Summary Adaptimmune Announces Appointment of Tal Zaks to Board of Directors
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the appointment of Tal Zaks , M.D., Ph.D., to its Board of Directors as an independent Non-Executive Director effective
Adaptimmune Announces Appointment of Tal Zaks to Board of Directors
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the appointment of Tal Zaks , M.D., Ph.D., to its Board of Directors as an independent Non-Executive Director effective
Toggle Summary Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present three posters  at the 2016 SITC annual meeting. The posters summarize: (1) preclinical data from
Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present three posters  at the 2016 SITC annual meeting. The posters summarize: (1) preclinical data from
Toggle Summary Adaptimmune to Report Third Quarter 2016 Financial Results on November 10, 2016
PHILADELPHIA and OXFORD, United Kingdom , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended September 30, 2016 before the open of the U.S.
Adaptimmune to Report Third Quarter 2016 Financial Results on November 10, 2016
PHILADELPHIA and OXFORD, United Kingdom , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended September 30, 2016 before the open of the U.S.
Toggle Summary Adaptimmune Announces Board Changes
PHILADELPHIA and OXFORD, United Kingdom , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced changes to its Board of Directors with the appointment of Giles Kerr and planned
Adaptimmune Announces Board Changes
PHILADELPHIA and OXFORD, United Kingdom , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced changes to its Board of Directors with the appointment of Giles Kerr and planned
Toggle Summary Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
PHILADELPHIA and OXFORD, United Kingdom , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck & Co., Inc.
Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
PHILADELPHIA and OXFORD, United Kingdom , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck & Co., Inc.
Toggle Summary Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
- Collaborative Study is First under Strategic Alliance with MD Anderson Cancer Center - PHILADELPHIA and OXFORD, United Kingdom , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a Phase
Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
- Collaborative Study is First under Strategic Alliance with MD Anderson Cancer Center - PHILADELPHIA and OXFORD, United Kingdom , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a Phase
Toggle Summary Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
PHILADELPHIA and OXFORD, United Kingdom , Oct. 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that its amended protocol using its NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in
Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
PHILADELPHIA and OXFORD, United Kingdom , Oct. 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that its amended protocol using its NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in
Toggle Summary Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an NY-ESO SPEAR® (Specific Peptide Enhanced
Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an NY-ESO SPEAR® (Specific Peptide Enhanced
Toggle Summary Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present a poster presentation of updated data on its lead clinical program, an NY-ESO SPEAR® (Specific Peptide
Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
PHILADELPHIA and OXFORD, United Kingdom , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present a poster presentation of updated data on its lead clinical program, an NY-ESO SPEAR® (Specific Peptide
Toggle Summary MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers
PHILADELPHIA and HOUSTON, United States and OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a
MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers
PHILADELPHIA and HOUSTON, United States and OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a
Toggle Summary Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization
PHILADELPHIA and OXFORD, United Kingdom , Sept. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing  agreement with PCT, a Caladrius company, (“PCT”) a
Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization
PHILADELPHIA and OXFORD, United Kingdom , Sept. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing  agreement with PCT, a Caladrius company, (“PCT”) a
Toggle Summary Adaptimmune to Participate in Two Upcoming Investor Conferences
PHILADELPHIA , and OXFORD, United Kingdom , Sept. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences: James Noble , Adaptimmune’s
Adaptimmune to Participate in Two Upcoming Investor Conferences
PHILADELPHIA , and OXFORD, United Kingdom , Sept. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences: James Noble , Adaptimmune’s
Toggle Summary Adaptimmune Reports Second Quarter 2016 Financial Results
 - Conference call to be held today at 8:00 AM ET ( 1:00 PM BST ) - PHILADELPHIA and OXFORD, United Kingdom , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results
Adaptimmune Reports Second Quarter 2016 Financial Results
 - Conference call to be held today at 8:00 AM ET ( 1:00 PM BST ) - PHILADELPHIA and OXFORD, United Kingdom , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results
Toggle Summary Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
PHILADELPHIA and OXFORD, United Kingdom , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
PHILADELPHIA and OXFORD, United Kingdom , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been
Toggle Summary Adaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016
PHILADELPHIA and OXFORD, United Kingdom , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended June 30, 2016 before the open of the U.S.
Adaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016
PHILADELPHIA and OXFORD, United Kingdom , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended June 30, 2016 before the open of the U.S.
Toggle Summary Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs PHILADELPHIA, Pa. and OXFORD, UK , July 28, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today
Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs PHILADELPHIA, Pa. and OXFORD, UK , July 28, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today
Toggle Summary Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European Commission has designated the company’s NY-ESO SPEAR ® T-cell therapy as an orphan medicinal
Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European Commission has designated the company’s NY-ESO SPEAR ® T-cell therapy as an orphan medicinal
Toggle Summary Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific’s Dynabeads™ CD3/CD28 Cell Therapy System
PHILADELPHIA and OXFORD, United Kingdom , June 21, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific .
Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific’s Dynabeads™ CD3/CD28 Cell Therapy System
PHILADELPHIA and OXFORD, United Kingdom , June 21, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific .
Toggle Summary Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive
Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive
Toggle Summary Adaptimmune to Present at the 2016 JMP Life Sciences Conference
PHILADELPHIA and OXFORD, United Kingdom , June 16, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe , Chief Financial Officer of Adaptimmune, will present at the 2016 JMP Life Sciences Conference
Adaptimmune to Present at the 2016 JMP Life Sciences Conference
PHILADELPHIA and OXFORD, United Kingdom , June 16, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe , Chief Financial Officer of Adaptimmune, will present at the 2016 JMP Life Sciences Conference
Toggle Summary Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
PHILADELPHIA and OXFORD, United Kingdom , June 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an affinity enhanced SPEAR™ T-cell receptor therapy
Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
PHILADELPHIA and OXFORD, United Kingdom , June 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an affinity enhanced SPEAR™ T-cell receptor therapy
Toggle Summary Adaptimmune to Present at the Jefferies 2016 Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom , June 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the Jefferies 2016 Healthcare Conference on
Adaptimmune to Present at the Jefferies 2016 Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom , June 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the Jefferies 2016 Healthcare Conference on
Toggle Summary Adaptimmune Announces Succession Plan for Chairman at End of 2016
PHILADELPHIA and OXFORD, United Kingdom , May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of
Adaptimmune Announces Succession Plan for Chairman at End of 2016
PHILADELPHIA and OXFORD, United Kingdom , May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of
Toggle Summary Adaptimmune Strengthens Board with Appointment of Barbara Duncan
PHILADELPHIA and OXFORD, United Kingdom , May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
PHILADELPHIA and OXFORD, United Kingdom , May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent
Toggle Summary Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom , May 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global Healthcare Conference on
Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom , May 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global Healthcare Conference on
Toggle Summary Adaptimmune Reports First Quarter 2016 Financial Results
PHILADELPHIA and OXFORD, United Kingdom , May 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2016 .
Adaptimmune Reports First Quarter 2016 Financial Results
PHILADELPHIA and OXFORD, United Kingdom , May 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2016 .
Toggle Summary Adaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom , May 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe , Chief Financial Officer of Adaptimmune, will present at the Bank of America Merrill Lynch 2016
Adaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom , May 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe , Chief Financial Officer of Adaptimmune, will present at the Bank of America Merrill Lynch 2016
Toggle Summary Adaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference
PHILADELPHIA and OXFORD, U.K. , April 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the Deutsche Bank
Adaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference
PHILADELPHIA and OXFORD, U.K. , April 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the Deutsche Bank
Toggle Summary Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day
PHILADELPHIA and OXFORD, United Kingdom , April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today hosted an Investor and Analyst meeting in New York and presented clinical and corporate updates that
Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day
PHILADELPHIA and OXFORD, United Kingdom , April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today hosted an Investor and Analyst meeting in New York and presented clinical and corporate updates that
Toggle Summary Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology
PHILADELPHIA and OXFORD, United Kingdom , April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide Enhanced Affinity
Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology
PHILADELPHIA and OXFORD, United Kingdom , April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide Enhanced Affinity
Toggle Summary Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board
PHILADELPHIA and OXFORD, United Kingdom , April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology experts from across the
Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board
PHILADELPHIA and OXFORD, United Kingdom , April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology experts from across the
Toggle Summary Adaptimmune to Host Analyst and Investor Day on April 22, 2016
PHILADELPHIA and OXFORD, U.K. , April 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company will host a live webcast in conjunction with its 2016 Analyst and Investor Day on
Adaptimmune to Host Analyst and Investor Day on April 22, 2016
PHILADELPHIA and OXFORD, U.K. , April 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company will host a live webcast in conjunction with its 2016 Analyst and Investor Day on
Toggle Summary Adaptimmune Announces New Vice President of Business Development, Wenyong Wang
PHILADELPHIA and OXFORD, United Kingdom , April 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that Dr. Wenyong Wang has joined the company as Vice President of Business Development. Dr.
Adaptimmune Announces New Vice President of Business Development, Wenyong Wang
PHILADELPHIA and OXFORD, United Kingdom , April 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that Dr. Wenyong Wang has joined the company as Vice President of Business Development. Dr.
Toggle Summary Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
PHILADELPHIA and OXFORD, United Kingdom , April 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the company’s
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
PHILADELPHIA and OXFORD, United Kingdom , April 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the company’s
Toggle Summary U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , March 30, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development has
U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , March 30, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development has
Toggle Summary Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
PHILADELPHIA and OXFORD, United Kingdom , March 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the six-month period ended December 31, 2015 .
Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
PHILADELPHIA and OXFORD, United Kingdom , March 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the six-month period ended December 31, 2015 .
Toggle Summary Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom , March 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at Cowen and
Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom , March 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at Cowen and
Toggle Summary Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference
PHILADELPHIA, Pa. and OXFORD, United Kingdom , Feb. 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the 2016 RBC
Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference
PHILADELPHIA, Pa. and OXFORD, United Kingdom , Feb. 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the 2016 RBC
Toggle Summary U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , Feb. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
PHILADELPHIA and OXFORD, United Kingdom , Feb. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy
Toggle Summary Adaptimmune to Participate in Two Upcoming Investor Conferences  
PHILADELPHIA and OXFORD, United Kingdom , Feb. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the following two
Adaptimmune to Participate in Two Upcoming Investor Conferences  
PHILADELPHIA and OXFORD, United Kingdom , Feb. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble , Chief Executive Officer of Adaptimmune, will present at the following two
Toggle Summary Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
PHILADELPHIA and OXFORD, United Kingdom , Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time ( 3:00 p.m.
Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
PHILADELPHIA and OXFORD, United Kingdom , Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time ( 3:00 p.m.
Toggle Summary Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trials Creates opportunity for up to eight combination studies   LONDON, PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trials Creates opportunity for up to eight combination studies   LONDON, PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a
Toggle Summary Adaptimmune Announces New Additions to Manufacturing Senior Management
PHILADELPHIA and OXFORD, United Kingdom , Jan. 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for clinical and commercial
Adaptimmune Announces New Additions to Manufacturing Senior Management
PHILADELPHIA and OXFORD, United Kingdom , Jan. 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for clinical and commercial
Toggle Summary Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications
PHILADELPHIA and OXFORD, United Kingdom , Jan. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it is expanding its T-cell therapy development activities to target certain autoimmune
Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications
PHILADELPHIA and OXFORD, United Kingdom , Jan. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it is expanding its T-cell therapy development activities to target certain autoimmune
Toggle Summary Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
PHILADELPHIA and OXFORD, United Kingdom , Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting
Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
PHILADELPHIA and OXFORD, United Kingdom , Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting
Toggle Summary Adaptimmune Wins Scrip Award for Financing Deal of the Year
PHILADELPHIA and OXFORD, United Kingdom , Dec. 03, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has won the Financing Deal of the Year Award at the 2015 Scrip awards.
Adaptimmune Wins Scrip Award for Financing Deal of the Year
PHILADELPHIA and OXFORD, United Kingdom , Dec. 03, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has won the Financing Deal of the Year Award at the 2015 Scrip awards.
Toggle Summary Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies
PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc. , a genome editing company developing universal donor stem cells, today
Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies
PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc. , a genome editing company developing universal donor stem cells, today
Toggle Summary Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
OXFORD, United Kingdom and PHILADELPHIA , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1
Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
OXFORD, United Kingdom and PHILADELPHIA , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1